Home Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...
 

Keywords :   


Short Regeneron: Further Downside Ahead For This Bloated Large-Cap...

2016-03-07 18:44:11| Biotech - Topix.net

Regeneron reported disappointing full-year 2015 results in early February, and once booming sales of EYLEA are starting to finally exhibit some sluggishness. The company's heavily-anticipated PCSK9 drug, Praluent, launched in mid-2015, but has yet to exhibit sales that were expected from the potential billion-dollar rock star.

Tags: short ahead downside bloated

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »